This document provides patient information for SPRYCEL (dasatinib) oral tablets, including indications, dosage, administration, warnings, and adverse reactions.
This document is the patient information leaflet for SPRYCEL (dasatinib), an oral tablet used to treat certain types of leukemia. It outlines the approved uses for adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The text details specific dosing regimens based on the type of leukemia and patient history, such as 100 mg daily for chronic phase CML and 140 mg daily for accelerated phase or Ph+ ALL. This manual is written in Chinese.
| Dosage for Chronic Phase CML | 100 mg once daily |
|---|---|
| Dosage for Accelerated Phase CML or Ph+ ALL | 140 mg once daily |
| Available Strengths | 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg |
The recommended starting dose is 100 mg taken orally once daily.
Tablets should be swallowed whole and should not be crushed or sliced. They can be taken with or without food.
The most common adverse reactions include bone marrow suppression, fluid retention, diarrhea, headache, musculoskeletal pain, and rash.